Genentech, Inc.: Phase 1 study in Advanced or Metastatic Breast Cancer (165 participants)
Genentech, Inc.: Phase 1 study in Advanced or Metastatic Breast Cancer (165 participants). Its enrollment of 165 is above the median of 80 (72nd percentile). Dated 26 days ago, it is in the active follow-up window. Score 60/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 165 · 72th percentile of 8,879 ClinicalTrialStartPulse records · 2.1x the median
Free preview: all 13 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Genentech, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer |
| NCT ID | NCT07867262 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Advanced or Metastatic Breast Cancer |
| Intervention types | drug |
| Target enrollment | 165 |
| Posted | 2026-10-09 |
| Planned start | 2026-12-15 |
| Event | Newly registered study |
| Event date | 2026-10-09 |
| enrollment percentile | 72th of 8,879 (median 80, 2.1x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Genentech, Inc.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Genentech + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-09
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Genentech, Inc. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Genentech, Inc.'s enrollment: 72nd percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
60 / 100 Score
- Industry sponsor (buys outsourced services).
- 165 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Genentech, Inc.?
Genentech, Inc. registered a Phase 1 study (NCT07867262) in Advanced or Metastatic Breast Cancer targeting 165 participants, posted 2026-10-09.
How does Genentech, Inc. compare to other ClinicalTrialStartPulse records?
Its enrollment of 165 sits in the upper half (72th percentile) of 8,879 records; the median is 80. It is 26 days old, still within a typical 45-day follow-up window.
Genentech, Inc. vs. top 2 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Genentech, Inc. | NONUS | 165 | 72nd | 2026-10-09 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | NONUS | 270 | 81st | 2026-11-03 |
| Mabsoft Therapeutics (Shanghai) Co., Ltd. | NONUS | 420 | 88th | 2026-10-28 |
Related records
- Hoffmann-La Roche
- MacroGenics
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
- Sutro Biopharma, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Genentech, Inc.
ClinicalTrialStartPulse: Phase 1 ClinicalTrialStartPulse: Outside the US only
How to monitor Genentech, Inc. and peer phase 1 records
Get new ClinicalTrialStartPulse records like Genentech, Inc. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.